Anand Mehta is a Partner in the Corporate and Commercial Practice group in the Mumbai office. He specialises in corporate acquisitions and mergers, India entry strategies, corporate & commercial laws and contract laws.
Over the years, Anand has assisted several clients including some Fortune 500 companies to establish and expand their India operations including forming joint ventures and other strategic alliances. He has actively participated in commercial negotiations for several multinational clients.
Anand advises clients in relation to employment, data privacy and other corporate fraud issues / white collar crimes issues from a preventive and compliance perspective. He helps clients conduct training sessions, supporting pre-investigation of employee investigation etc.
Corporate and Commercial
Privacy and Data Protection
White Collar Crimes and Investigations
Estate Planning, Trusts and Private Client
Pharmaceuticals
Advised on US$ 1.2 billion takeover of Fortis Healthcare Limited comprising of a primary infusion and consequent open offers at Fortis as well as its listed subsidiary, Fortis Malar Hospital Limited.
Advised on US$ 194 million investment in RGE Medical Associates comprising of a primary equity infusion and secondary purchases from multiple exiting financial investors and some stake sold by the promoters.
Advised on acquisition of the business of freight logistics marketplace Dipper Technologies in a cash and stock transaction.
Advised on strategic Indian outsourcing joint venture with Nomura, Inc.
Advised in relation to sale of animal health division to Sanofi Synthelabo (India) Limited for, creating a market entry for Merial (Animal Health division of Sanofi) in India.
Advised on acquisition of the entire intangible assets, including the trademarks of “NOMARKS” brand from Ozone Ayurvedics, India and Ozone UK Limited.
Advised on the sale of a 60% stake in Spectro to Eurofins Environment Testing Lux Holding SARL (Eurofins) through a mix of primary and secondary acquisitions; and
Advised on acquisition of certain assets of Kilitch Drugs (India) Ltd, as well as certain assets of NBZ Pharma Limited, for approximately USD 52 million in cash and future contingent payments totaling up to approximately USD 6 million.
Advised on acquisition of 51% stake in Rex Polyextrusion Private Limited (Rex) for a consideration of INR 75.2 crores and subsequent amalgamation of Rex into Astral.
